Sentinel lymph nodes in endometrial cancer: is hysteroscopic injection valid?

Eur J Gynaecol Oncol. 2008;29(3):239-41.

Abstract

We aimed to describe hysteroscopic peritumoral tracer injection for detecting sentinel lymph nodes (SLNs) in patients with endometrial cancer and to evaluate tolerance of the procedure, detection rate and location of SLNs. Five patients with early endometrial cancer underwent hysteroscopic radiotracer injection followed by lymphoscintigraphy, then by surgery with hysteroscopic peritumoral blue dye injection, and radioactivity measurement using an endoscopic handheld gamma probe. SLNs and other nodes were sent separately to the pathology laboratory. SLNs were evaluated by hematoxylin-eosin-saffron staining and, when negative, by immunohistochemistry. Tolerance of the injection by the patients was poor (mean visual analog scale score, 8/10). SLNs were detected in only two patients (external iliac and common iliac+paraaortic, respectively). Detection rates were 1/5 by radiotracer, 1/5 by dye, and 2/5 by the combined method. One SLN was involved in a patient whose other nodes were negative. In three patients no SLNs were found by radiotracer or blue dye. Of the 83 non sentinel nodes removed from these patients, none was involved. Hysteroscopic peritumoral injection may be more difficult than cervical injection and, in our experience, carries a lower SLN detection rate.

Publication types

  • Validation Study

MeSH terms

  • Coloring Agents
  • Endometrial Neoplasms / diagnostic imaging
  • Endometrial Neoplasms / pathology*
  • Endometrial Neoplasms / surgery
  • Female
  • Humans
  • Hysteroscopy / methods*
  • Injections / adverse effects
  • Lymph Nodes / pathology
  • Lymph Nodes / surgery
  • Radionuclide Imaging
  • Sentinel Lymph Node Biopsy / methods*
  • Uterine Neoplasms / diagnostic imaging
  • Uterine Neoplasms / pathology*
  • Uterine Neoplasms / surgery

Substances

  • Coloring Agents